QRM Tools for Contract Biomanufacturing

Publication
Article
BioPharm InternationalBioPharm International-06-15-2015
Volume 2015 eBook
Issue 1

Quality-risk management tools can assist biopharma companies in mitigating risks when outsourcing crucial elements of the drug-development process.

 

For decision making and overall program risk reduction, a quality-risk-management (QRM) program is an effective means for biotech companies to mitigate the risks associated with outsourcing crucial elements of the drug-development lifecycle. Risks only get larger when activities typically performed internally during the development process are outsourced to a contract service provider.

 

Download

BioPharm International’s 2015 Outsourcing Resources eBook

.

 

 

 

 

 

Articles in this issue
BPsupp0615__QRM_200.jpg
QRM Tools for Contract Biomanufacturing
BPsupp0615_LangerFillFinish_200.jpg
Fill/Finish Trends
BPsupp0615_Feature_roundtable_200.jpg
Biopharma Advances Demand Specialized Expertise
BPsupp0615_IPLaw_200.jpg
Protecting Intellectual Property in Engagements with CMOs
BPsupp0615_Neostem_200.jpg
Taking a “Development-by-Design” Approach to Cell Therapies
Recent Videos
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Abzena Launches GMP Cell-Based Potency Testing in US and UK Sites, Boosting Analytical Capabilities

Feliza Mirasol
November 22nd 2024
Article

The company will now include GMP cell-based potency assays at its Cambridge, UK, and San Diego, Calif., sites expanding its early and late phase analytical capabilities.

Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically

Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically

Felicity Thomas
May 25th 2023
Podcast

Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

SEKISUI Completes CDMO Capacity Expansion for CGMP Biopharma Manufacturing

Feliza Mirasol
November 19th 2024
Article

Under a £15.7 million (US$20.7 million) investment, SEKISUI has expanded its UK site for clinical-grade drug substance manufacturing.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

FDA Approves PTC Therapeutics’ Gene Therapy for AADC Deficiency

Feliza Mirasol
November 18th 2024
Article

The approval of eladocagene exuparvovec-tneq (Kebilidi) marks the first FDA approval for a gene therapy to treat AADC deficiency.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Lecanemab Gets Nod from CHMP for Use in Early Alzheimer’s Disease

Felicity Thomas
November 15th 2024
Article

Eisai Europe and Biogen have received a positive opinion for the monoclonal antibody therapy to be used as a treatment of adult patients with early Alzheimer’s disease.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Budget Announcement Prompts UK Medicines Manufacturing Skills Centre to Emphasize Need for Skills Development

Susan Haigney
November 11th 2024
Article

Chancellor of the Exchequer, Rachel Reeves, has announced a £520 million (US$675 million) investment for manufacturing capacity in the United Kingdom, prompting academic and industry leaders to point out that funds should be used to train personnel.

© 2024 MJH Life Sciences

All rights reserved.